Therapeutic Strategies and Clinical Trials in Long COVID: Anticoagulants, Fibrinolytics, Endothelial Support, Immunomodulators, and RECOVER Protocols

Author: John Murphy, President, COVID-19 Long-haul Foundation Abstract Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is a chronic multisystem condition affecting millions globally. Despite its prevalence, therapeutic options…[...]

Read More

COVID Research Gaps and Future Directions: Standardization, Longitudinal Recovery, AI-Driven Biomarkers, and Policy Reform

Author: John Murphy, President, COVID-19 Long-haul Foundation Abstract Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), remains a poorly defined and under-researched condition affecting millions globally. Despite its prevalence,…[...]

Read More

Systemic Reluctance: Medical Inertia and the Pharmaceutical Industry’s Influence on Long COVID Treatment

Abstract Despite the global burden of Long COVID, the medical profession has demonstrated a striking reluctance to engage in consistent diagnosis, treatment, and research. This article explores the multifactorial roots…[...]

Read More

FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots

By  LAURAN NEERGAARD and MATTHEW PERRONE WASHINGTON (AP) — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing uncertainty about updates to other…[...]

Read More